top of page
InhaLac® 400

InhaLac® 400

MEGGLE has developed a specialty lactose grade, InhaLac®, to help meet the challenges associated with dry powder inhalation (DPI).
Inhalation aerosols offers the potential for needle-free systemic delivery of small molecule drugs as well as therapeutic peptides and proteins.  An industry standard in dry power inhalation formulation development, lactose monohydrate is used safely in DPI formulations. Using lactose as an excipient not only improves performance efficiency of the inhaler, but also facilitates powder handling during production. Effective performance of a dry powder inhaler largely depends on the carrier material used for the drug formulation.
With our highly controlled production process different high quality sieved and milled grades are obtained, providing an adequate range of particle sizes – making them behave as individual particles.
Particle size distribution
[Laser diffraction]
x10: 0.8-1.6 µm
x50: 4.0-11.0 µm
x90: 15.0-35.0 µm
Typical Values
Bulk Density [g/l]: 330
Tapped Density [g/l] : 530
Hausner factor: 1.61
Carrs index: 38 %
  • INCI

  • Generic and alternative names

    Lactose Monohydrate, Inhalation
  • Claims / benefits / efficacy

    Dedicated production process Tailor-made products with specific powder characteristics Highest microbial quality including low endotoxins Available in a broad spectrum of sieve cuts to meet your criteria
  • Function

    diluents; fillers
  • Application

    With InhaLac®, MEGGLE can offer customized milled and sieved fractions - specifically and efficiently prepared to meet your DPI formulation needs.
bottom of page